Mobile Logo in White

Greehey CCRI Archives

Filter results


Molecular Cancer Theraputics: Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium (Houghton, Kurmasheva)

August 3, 2022

Pooja Hingorani Wendong Zhang; Zhongting Zhang; Zhaohui Xu; Wei-Lien Wang; Michael E. Roth Yifei Wang; Jonathan B. Gill Douglas J. Harrison; Beverly A. Teicher; Stephen W. Erickson Gregory Gatto; Edward A. Kolb Malcolm A. Smith Raushan T. Kurmasheva Pe …


Clinical Cancer Research: Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models (Houghton & Kurmasheva)

August 1, 2022

Fuyang Li; Kathryn M. Bondra; Samson Ghilu; Adam Studebaker; Qianqian Liu Joel E. Michalek Mari Kogiso; Xiao-Nan Li John A. Kalapurakal; C. David James; Sandeep Burma; Raushan T. Kurmasheva Peter J. Houghton Abstract Purpose: We investigated why three …


Dr. Raushan Kurmasheva Received the CURE Childhood Cancer Award

June 24, 2022

Abstract Atypical teratoid/rhabdoid tumors (AT/RT) of the brain and malignant rhabdoid tumors of the kidney (RTK) compose a group of highly malignant pediatric cancers known as malignant rhabdoid tumors (MRT). Both subtypes are characterized by the bia …


Molecular Cancer Therapeutics: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma (Houghton, Kurmasheva)

June 1, 2022

Yifei Wang; Xiangjun Tian; Wendong Zhang; Zhongting Zhang; Rossana Lazcano; Pooja Hingorani; Michael E. Roth; Jonathan D. Gill; Douglas J. Harrison; Zhaohui Xu; Sylvester Jusu; Sankaranarayanan Kannan; Jing Wang; Alexander J. Lazar; Eric J. Earley; Ste …


Clinical Cancer Research: The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models (Kurmasheva & Houghton)

April 22, 2022

Nathan M Kendsersky # 1 2, Jarrett Lindsay # 1 2, E Anders Kolb 3, Malcolm A Smith 4, Beverly A Teicher 4, Stephen W Erickson 5, Eric J Earley 5, Yael P Mosse 1, Daniel Martinez 6, Jennifer Pogoriler 2 6, Kateryna Krytska 1, Khushbu Patel 1 7, David Gr …


Dr. Kurmasheva to be Awarded Helen Freeborn Kerr Charitable Foundation Grant

April 18, 2022


Journal of Pediatric Hematology/Oncology: Extrarenal Anaplastic Wilms Tumor A Case Report With Genomic Analysis And Tumor Models (Kurmasheva & Houghton)

February 8, 2022

Willis, Kelsi R. MS*; Sathe, Adwait A. PhD†; Xing, Chao PhD†,‡,§; Koduru, Prasad PhD*; Artunduaga, Maddy MD∥,¶; Butler, Erin B. MD#; Park, Jason Y. MD, PhD*,¶; Kurmasheva, Raushan T. PhD**,††; Houghton, Peter J. PhD**,††; Chen, Kenneth S. MD¶,#; Rakhej …


iScience: PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma (Kurmasheva & Houghton Labs)

January 18, 2022

Vanessa del Pozo Andrew J.Robles Shaun D.Fontaine QianqianLiu Joel E.Michalek Peter J.Houghton Raushan T.Kurmasheva Highlights Nanoparticle-formulated drugs minimize drug-induced toxicity PEG∼TLZ enhances in vivo activity of TMZ in pediatric tumor xeno …


Pediatric Blood & Cancer: In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC) (Kurmasheva, Houghton)

August 30, 2021

Raushan T. Kurmasheva, Stephen W. Erickson, Ruolan Han, Beverly A. Teicher, Malcolm A. Smith, Michael Roth, Richard Gorlick, Peter J. Houghton Abstract SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed …


Drs Houghton and Kurmasheva to Receive 5-year, $2.9M NCI Pediatric In Vivo Testing Program (PIVOT) U01 Grant Renewal

August 10, 2021

NCI Pediatric In Vivo Testing Program (U01), renewal for the previous PPTC (Pediatric Preclinical Testing Consortium). Grant period:            July 2021-June 2026. Total dollar amount:  $2,900,000 over 5 years. Abstract Cancer in children is rare with …